Table 2.
Outcomes of the selected studies.
| Study | Sample Size | Implantation Rate | Biochemical Pregnancy Rate | Clinical Pregnancy Rate | Live Birth Rate | Miscarriage Rate | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | PRP | Control | PRP | Control | PRP | Control | PRP | Control | PRP | Control | PRP | |
| Allahveisi et al., 2020 | 25 | 25 | 36% (n = 9) |
28% (n = 7) |
NR | NR | 36% (n = 9) |
28% (n = 7) |
28% (n = 6) |
24% (n = 7) |
NR | NR |
| Eftekhar et al., 2018 | 43 | 40 | 9.37% * | 21% * | 24.2% (n = 8) |
42.4% (n = 14) |
18.2% (n = 6) |
39.4% (n = 13) |
18.2% (n = 6) |
33.3% (n = 11) |
6% (n = 2) |
9% (n = 3) |
| Ershadi et al., 2022 | 45 | 40 | 0.38 ± 0.16% | 0.36 ± 0.24% | 27% (n = 12) | 40% (n = 16) | 24% (n = 11) | 33% (n = 13) | NR | NR | 31.25% (n = 5) | 8.33% (n = 1) |
| Nazari et al., 2020 | 48 | 49 | NR | NR | 27.08% (n = 13) |
53.06% (n = 26) |
16.66% (n = 8) |
44.89% (n = 22) |
NR | NR | NR | NR |
| Nazari et al., 2019 | 30 | 30 | NR | NR | 6.7% (n = 2) |
40% (n = 12) |
3.3% (n = 1) |
33.3% (n = 10) |
NR | NR | NR | NR |
| Nazari et al., 2021 | 197 | 196 | NR | NR | 24.87% (n = 49) |
51.53% (n = 101) |
19.28% (n = 38) |
48.97% (n = 96) |
5.58% (n = 11) |
39.28% (n = 77) |
NR | NR |
| Nazari et al., 2022 | 20 | 20 | NR | NR | NR | NR | 20% (n = 4) | 35% (n = 7) | 0% (n = 0) | 15% (n = 3) | 20% (n = 4) | 20% (n = 4) |
| Obidniak et al., 2017 | 45 | 45 | 20.9% * | 40.5% * | NR | NR | 24.4% (n = 11) |
53.3% (n = 24) |
NR | NR | NR | NR |
| Zamaniyan et al., 2020 | 43 | 55 | 34.9% (n = 15) |
63.6% (n = 35) |
23.3% (n = 10) |
36.2% (n = 20) |
23.3% (n = 10) |
52.7% (n = 29) |
NR | NR | 4.6% (n = 2) |
1.8% (n = 1) |
| Zargar et al., 2021 | 40 | 40 | 5% (n = 2) |
15% (n = 6) |
NR | NR | 2.5% (n = 1) |
12.5% (n = 5) |
2.5% (n = 1) |
12.5% (n = 5) |
2.5% (n = 1) |
2.5% (n = 1) |
* Data excluded from the meta-analysis; NR: not reported.